Market cap
$203 Mln
Revenue (TTM)
$38 Mln
P/E Ratio
--
P/B Ratio
88.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 38.53 | 166.66 | 354.37 | 176.15 | 47.08 |
| EBIT | -1,595.61 | -939.84 | -155.70 | -55.03 | -174.88 |
| Net Profit | -2,856.10 | -1,704.61 | -321.93 | -205.24 | -211.67 |
| EPS | -2,141.27 | -805.61 | -63.39 | 8.90 | 6.66 |
| Book Value | -- | -- | 1.47 | -47.75 | -38.24 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -474.85 | -1,183.53 | -260.64 | -93.73 | -429.40 |
| Net Margin
| -- | -- | -435.83 | -- | -- |
| Return on equity
| -122.96 | -102.17 | -1,141.94 | -121.11 | -149.03 |
| Return on Capital
| -90.53 | -78.17 | -- | -93.33 | -104.09 |
| Return on Assets
| -74.90 | -66.74 | -279.83 | -71.51 | -86.80 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.16 | 0.51 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
--
|
-93.33
|
-104.09
|
-74.18
|
-65.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-1,141.94
Lower than Peers by 1,101.54
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-1,141.94
|
-121.11
|
-149.03
|
-98.73
|
-80.82
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-279.83
Lower than Peers by 248.85
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-279.83
|
-71.51
|
-86.80
|
-66.40
|
-60.69
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-260.64
Lower than Peers by 177.02
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-260.64
|
-93.73
|
-429.40
|
-901.42
|
-4,200.56
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-435.83
Lower than Peers by 343.16
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-435.83
|
-96.85
|
-437.97
|
-924.10
|
-4,257.83
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
354.37
Higher than Peers by 300.42
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
354.37
|
1.96
|
0.69
|
3.41
|
-0.92
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-155.70
Lower than Peers by 154.90
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-155.70
|
35.44
|
19.42
|
5.37
|
-19.64
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-321.93
Lower than Peers by 314.62
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-321.93
|
34.60
|
19.83
|
4.30
|
-20.04
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-63.39
Lower than Peers by 78.04
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-63.39
|
0.56
|
0.49
|
0.20
|
0.03
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-93.62
Lower than Peers by 83.44
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-93.62
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
--
|
0.16
|
0.51
|
0.40
|
0.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.70
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
0.70
|
0.07
|
0.45
|
0.20
|
0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.25
Lower than Peers by 4.55
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
1.25
|
2.74
|
1.84
|
3.01
|
6.68
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.25
Lower than Peers by 4.44
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
1.25
|
--
|
--
|
3.01
|
6.68
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-1,210.91
Lower than Peers by 1,208.82
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-1,210.91
|
-72.11
|
-50.10
|
-39.75
|
-73.26
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
19.32
Higher than Peers by 0.18
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
19.32
|
27.11
|
10.18
|
30.93
|
4.58
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.64
Higher than Peers by 0.58
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
0.64
|
0.74
|
0.20
|
0.07
|
0.01
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
--
|
55.79
|
51.97
|
58.38
|
469.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
--
|
--
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
--
|
355.33
|
491.46
|
29.87
|
538.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
--
|
--
|
-439.48
|
28.51
|
-68.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
--
|
-0.04
|
-0.07
|
-0.08
|
-0.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
88.56
Higher than Peers by 83.38
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
88.56
|
0.04
|
0.15
|
0.11
|
0.06
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-1.76
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
-1.76
|
0.98
|
0.31
|
0.64
|
1.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
203
Higher than Peers by 56
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
|
203
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|